<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581265</url>
  </required_header>
  <id_info>
    <org_study_id>nab-PTX-sun</org_study_id>
    <nct_id>NCT04581265</nct_id>
  </id_info>
  <brief_title>Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor.</brief_title>
  <official_title>A Multicenter Phase II Clinical Study of Albumin-bound Paclitaxel (Nab-PTX), Ifosfamide and Cisplatin in the Treatment of Pediatric Advanced, Recurrent or Refractory Extracranial Germ Cell Tumor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the effectiveness and safety of albumin-bound paclitaxel&#xD;
      (nab-PTX), ifosfamide and cisplatin in the treatment of children patients with advanced,&#xD;
      recurrent or refractory extracranial germ cell tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children patients with advanced, recurrent or refractory extracranial germ cell tumor were&#xD;
      treated with albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin . This is a&#xD;
      multi-center and single arm phase II clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2020</start_date>
  <completion_date type="Anticipated">May 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate，ORR</measure>
    <time_frame>From the beginning of observation to the 2 cycles of observation(each cycle is 21 days)</time_frame>
    <description>Percentage of participants who experienced an overall response (overall response rate，ORR) of albumin-binding paclitaxel, ifosfamide, cisplatin regimen in the treatment of advanced, recurrent and refractory children with extracranial germ cell tumor.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Extracranial Germ Cell Tumor, Pediatric</condition>
  <arm_group>
    <arm_group_label>nab-PTX, ifosfamide and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin</intervention_name>
    <description>Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.</description>
    <arm_group_label>nab-PTX, ifosfamide and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 1-18 years old;&#xD;
&#xD;
          2. ECOG PS score: 0-1;&#xD;
&#xD;
          3. Patients was confirmed pathologically with malignant germ cell tumor.&#xD;
&#xD;
          4. Patients with tumor progressed, relapsed or refractory after first-line chemotherapy,&#xD;
             and complete or partial remission was not achieved after recent treatment.&#xD;
&#xD;
          5. Have at least one measurable lesion defined by RECIST standard;&#xD;
&#xD;
          6. The estimated survival time was more than 6 months;&#xD;
&#xD;
          7. Patients must fully recover from the acute toxicity of previous anticancer&#xD;
             chemotherapy:&#xD;
&#xD;
          8. Bone marrow function met the following criteria:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.0 × 109 / L;&#xD;
&#xD;
               2. Platelet count ≥ 100.0 × 109 / L (not after platelet transfusion);&#xD;
&#xD;
          9. Liver and kidney function should meet the following criteria:&#xD;
&#xD;
               1. Bilirubin (the sum of bound and unconjugated) ≤ 1.5 × upper limit of normal value&#xD;
                  (ULN) (corresponding to age). Patients with confirmed Gilbert's syndrome can be&#xD;
                  classified according to the researcher;&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN;&#xD;
&#xD;
               3. Estimated glomerular filtration rate ≥ 70 ml / min / 1.73 m2 or normal serum&#xD;
                  creatinine (CR);&#xD;
&#xD;
         10. Adequate pulmonary function: no dyspnea at rest, no exercise intolerance, pulse oxygen&#xD;
             saturation &gt; 94% (if there are clinical symptoms);&#xD;
&#xD;
         11. Cardiac function:&#xD;
&#xD;
               1. LVEF ≥ 50% was detected by echocardiography;&#xD;
&#xD;
               2. There was no history of arrhythmia requiring drug intervention before enrollment;&#xD;
&#xD;
         12. Seizures that can be fully controlled without enzyme-induced anticonvulsants;&#xD;
&#xD;
         13. During the study period, they were able to comply with outpatient treatment,&#xD;
             laboratory monitoring and necessary clinical visits;&#xD;
&#xD;
         14. Parents / guardians of child or adolescent subjects have the ability to understand,&#xD;
             agree and sign the study informed consent form (ICF) and the applicable child consent&#xD;
             form before starting any program related procedures; subject has the ability to&#xD;
             express consent (when applicable) with the consent of parents / guardians.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the following items will not be enrolled in this study:&#xD;
&#xD;
          1. Patients with recurrent germ cell tumor were treated by surgery alone previously;&#xD;
&#xD;
          2. Patients with immature teratoma (any grade);&#xD;
&#xD;
          3. Patients with sex cord stroma;&#xD;
&#xD;
          4. HBsAg positive patients;&#xD;
&#xD;
          5. Patients with HIV or syphilis infection;&#xD;
&#xD;
          6. Patients who had received organ transplantation before;&#xD;
&#xD;
          7. Uncontrolled active systemic bacterial, viral or fungal infections;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhuo Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University CancerCenter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yizhuo Zhang</last_name>
    <phone>020-87342459</phone>
    <email>zhangyzh@sysucc.org.cn</email>
  </overall_contact>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yizhuo Zhang</investigator_full_name>
    <investigator_title>Director of department of pediatric cancer,Principal Investigator,Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

